Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

Psychopharmacology (Berl)
July 2010
https://pubmed.ncbi.nlm.nih.gov/20386884/

Rationale: Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute and chronic pain. Opioid analgesics with decreased risk for abuse are needed.

The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis

Sleep Medicine Reviews
October 2018
https://www.sciencedirect.com/science/article/abs/pii/S1087079217301521

Mark Shuhkman, MD and Andrey Lev-Weissberg, MD - Psychiatric Disorders (2013 Conference) (LDN, low dose naltrexone)

Low-dose Naltrexone for atopic dermatitis?

National Eczema Association
11 April 2019
https://nationaleczema.org/naltrexone/

Dr Mark Shukhman - LDN in Psychiatry (2014 Conference) (LDN, low dose naltrexone)

Use of LDN for Chronic Pain - Sahar Swidan, PHARM.D., ABAAHP, FAARFM, FACA (2021 Conference) (LDN, low dose naltrexone)

This talk is on the use of LDN for chronic pain. She reviews LDN’s actions in the CNS and the PNS, the immunomodulating effect of LDN, and some clinical trials on the use of LDN.

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

PTSD and other mental health treatment with opioid antagonist... - Galyn Forster, MS, LPC (2021 Conference) (LDN, low dose naltrexone)